Cabio Biotech has issued its 2026 half-year performance forecast, expecting a net loss attributable to owners of the parent company of about 101 million yuan for the first half, compared with a profit of 108 million yuan in the same period last year. The company said that due to the impact of overseas market sentiment and new regulatory requirements, production plans were adjusted and business recovery measures were taken, but product production and sales have not yet fully recovered, resulting in a significant gap in overall performance compared with the same period last year.
Cabio Biotech Wuhan Co LtdCompany expects net loss due to overseas market sentiment and new regulatory requirements impacting production and sales.